Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MRG007
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Arrivent
Deal Size : $1,207.0 million
Deal Type : Licensing Agreement
ArriVent, Lepu Sign Exclusive License for MRG007 in GI Cancer Treatment
Details : Under the terms of the agreement, Lepu Biopharma has granted ArriVent exclusive global rights to develop, manufacture and commercialize MRG007 outside of Greater China.
Product Name : MRG007
Product Type : Antibody-drug Conjugate
Upfront Cash : $47.0 million
January 21, 2025
Lead Product(s) : MRG007
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Arrivent
Deal Size : $1,207.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Pucotenlimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Hanx Biopharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Puyouheng (pucotenlimab injection) is a humanized IgG4 monoclonal antibody against human PD-1, bind to PD-1 with high affinity to restore the ability of immune cells to kill cancer cells by blocking the binding of PD-1 to its ligands PD-L1 and PD-L2.
Product Name : Puyouheng
Product Type : Antibody
Upfront Cash : Inapplicable
July 25, 2022
Lead Product(s) : Pucotenlimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Hanx Biopharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable